|
Oct 3
|
Here's Why You Should Add AngioDynamics Stock to Your Portfolio
|
|
Oct 3
|
AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates
|
|
Oct 3
|
AngioDynamics: Fiscal Q1 Earnings Snapshot
|
|
Oct 3
|
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
|
|
Sep 30
|
New Strong Buy Stocks for September 30th
|
|
Sep 23
|
ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe
|
|
Sep 4
|
AngioDynamics Stock Falls Despite CE Mark for Auryon System
|
|
Sep 4
|
AngioDynamics wins EU CE mark for Auryon system to treat PAD
|
|
Sep 3
|
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
|
|
Sep 1
|
TipRanks ‘Perfect 10’ List: 2 Top-Scoring Stocks Worth Watching
|
|
Aug 27
|
AngioDynamics (ANGO) Upgraded to Strong Buy: Here's Why
|
|
Jul 29
|
AngioDynamics to Participate in Upcoming Investor Conferences
|
|
Jul 29
|
Wall Street Analysts Predict a 74.25% Upside in AngioDynamics (ANGO): Here's What You Should Know
|
|
Jul 28
|
AngioDynamics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line
|
|
Jun 13
|
First patient implanted with Philips’ Duo Venous stent system
|
|
May 22
|
AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval
|
|
May 22
|
Investors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 75% over the last three years
|
|
May 21
|
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
|
|
May 6
|
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
|
|
May 2
|
Oppenheimer Predicts Over 100% Rally for These 2 Healthcare Stocks
|